JP2024517443A - がんの治療に有用なモレファンチン誘導体 - Google Patents

がんの治療に有用なモレファンチン誘導体 Download PDF

Info

Publication number
JP2024517443A
JP2024517443A JP2023566885A JP2023566885A JP2024517443A JP 2024517443 A JP2024517443 A JP 2024517443A JP 2023566885 A JP2023566885 A JP 2023566885A JP 2023566885 A JP2023566885 A JP 2023566885A JP 2024517443 A JP2024517443 A JP 2024517443A
Authority
JP
Japan
Prior art keywords
cancer
compound
substituted
unsubstituted
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023566885A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024517443A5 (https=
Inventor
ヨン リィ，ホイ
俊介 千葉
クアン ライ，ソーク
ジー コー，チョン
ワー ローランド オン，トゥーン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nanyang Herbs Pte Ltd
Original Assignee
Nanyang Herbs Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanyang Herbs Pte Ltd filed Critical Nanyang Herbs Pte Ltd
Publication of JP2024517443A publication Critical patent/JP2024517443A/ja
Publication of JP2024517443A5 publication Critical patent/JP2024517443A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/93—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2023566885A 2021-04-29 2022-04-27 がんの治療に有用なモレファンチン誘導体 Pending JP2024517443A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SG10202104429U 2021-04-29
SG10202104429U 2021-04-29
PCT/SG2022/050251 WO2022231520A1 (en) 2021-04-29 2022-04-27 Molephantin derivatives useful in the treatment of cancer

Publications (2)

Publication Number Publication Date
JP2024517443A true JP2024517443A (ja) 2024-04-22
JP2024517443A5 JP2024517443A5 (https=) 2025-06-11

Family

ID=83848883

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023566885A Pending JP2024517443A (ja) 2021-04-29 2022-04-27 がんの治療に有用なモレファンチン誘導体

Country Status (7)

Country Link
US (1) US20250304544A1 (https=)
EP (1) EP4330241A4 (https=)
JP (1) JP2024517443A (https=)
CN (1) CN117377663A (https=)
AU (1) AU2022265461A1 (https=)
IL (1) IL308058A (https=)
WO (1) WO2022231520A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115919833A (zh) * 2023-01-31 2023-04-07 暨南大学附属第一医院（广州华侨医院） 一种CutC蛋白抑制剂及其应用
AU2024337402A1 (en) * 2023-09-06 2026-03-26 Nanyang Biologics Pte. Ltd. Collective synthesis of phantomolin family through total synthesis of the sesquiterpene lactone molephantin

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019040335A1 (en) * 2017-08-19 2019-02-28 University Of Rochester MICHELOLID DERIVATIVES, PREPARATION METHODS AND THEIR USE AS ANTICANCER AND ANTI-INFLAMMATORY AGENTS

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3418724B2 (ja) * 2000-02-10 2003-06-23 国立医薬品食品衛生研究所長 セスキテルペノイド化合物及びそれを含む医薬
JP2005002050A (ja) * 2003-06-12 2005-01-06 Shiseido Co Ltd 美白剤及びこれを配合した皮膚外用剤
CN102000072A (zh) * 2009-09-01 2011-04-06 奇复康药物研发(苏州)有限公司 偶联有一氧化氮供体的抗肿瘤天然药物及其医药用途
CN103732586B (zh) * 2011-04-07 2016-02-03 南洋理工大学 作为抗癌剂的乙酰基丹参酮iia(ata)
CN111153910B (zh) * 2020-01-09 2021-07-30 沈阳药科大学 地胆草种内酯衍生物及其制备方法和用途

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019040335A1 (en) * 2017-08-19 2019-02-28 University Of Rochester MICHELOLID DERIVATIVES, PREPARATION METHODS AND THEIR USE AS ANTICANCER AND ANTI-INFLAMMATORY AGENTS

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LEE, KUO-HSIUNG; IBUKA, TOSHIRO; FURUKAWA, HIROSHI; KOZUKA, MUTSUO; WU, RONG-YANG; HALL, IRIS H.; HU: "Antitumor agents. XXXVIII: Isolation and structural elucidation of novel germacranolides and trite", JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 69(9), JPN7026000171, 1980, pages 1050 - 1056, ISSN: 0005781860 *

Also Published As

Publication number Publication date
AU2022265461A1 (en) 2023-11-16
IL308058A (en) 2023-12-01
US20250304544A1 (en) 2025-10-02
EP4330241A4 (en) 2025-03-19
EP4330241A1 (en) 2024-03-06
WO2022231520A1 (en) 2022-11-03
CN117377663A (zh) 2024-01-09

Similar Documents

Publication Publication Date Title
AU2014340182B2 (en) Cromolyn derivatives and related methods of imaging and treatment
US20250074873A1 (en) Compounds
WO2022199627A1 (en) Polycyclic compounds and uses thereof
JP2024517443A (ja) がんの治療に有用なモレファンチン誘導体
EP3245189B1 (en) Modulators of ca2+ release-activated ca2+ (crac) channels and pharmaceutical uses thereof.
ES2928666T3 (es) Piridinetionas, sus composiciones farmacéuticas y su uso terapéutico para el tratamiento de enfermedades proliferativas, inflamatorias, neurodegenerativas o inmunomediadas
WO2017112951A1 (en) Cftr regulators and methods of use thereof
AU2006216031A1 (en) Anti-tumor agent
JP7664861B2 (ja) 眼障害の治療のための化合物
BRPI0710538A2 (pt) processo para a sìntese de um estereoisÈmero substancialmente puro, compostos, composição farmacêutica que compreende um composto, processo para a sìntese de um composto e uso do mesmo.
CN103304573A (zh) 石蒜碱类化合物在制备抗肿瘤药物的应用
WO2019052477A1 (zh) 丹参酮类化合物及其用于治疗血管瘤的用途
EP3307724B1 (en) (z)-2-(1h-indol-3-yl)-3-(isoquinolin-5-yl)acrylonitrile derivatives and related compounds with lysosome inhibitory and anti-mitotic activity for treating hyperproliferative diseases
WO2025247285A1 (zh) 一种可抑制il-17a的杂环化合物制备及其用途
WO2023040810A1 (en) Methods of cancer treatment using a combination of btk inhibitors and pi3 kinase inhibitors
WO2024235218A1 (zh) Hdac1/2选择性抑制剂及其用途
CN114149395B (zh) 一种苯并环戊烯酮衍生物、其制备方法及医药用途
CN121127460A (zh) 可用作治疗剂的新型化合物
CN116761598A (zh) Fabp4调节化合物的抗病毒用途
CN110709079B (zh) 包含1，2-萘醌衍生物化合物的实体癌或血液癌的预防或治疗用药物组合物
CN117700419A (zh) 一氧化氮供体型咔唑衍生物及其在治疗肿瘤疾病中的用途
JP2024510249A (ja) 神経疾患を治療するための組成物およびその方法
US11141402B2 (en) Compounds useful in inhibiting human trefoil factor 3
WO2025043213A2 (en) Therapeutic compounds and methods
CN103374001B (zh) 咪唑并三嗪类mTOR抑制剂

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20250418

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250425

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250425

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20250418

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20251225

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260127

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260423